A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable ...

Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain ...

A woman who was told she would “probably die” from skin cancer has spoken of her shock and joy at being told her tumours had ...

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.

Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...

We know from the phase 2 TROPHY-U-01 trial that sacituzumab govitecan is an active drug, with an objective response rate of ...

A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved ...

In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus ...

Investigators used the Shiny method, which employs artificial intelligence, to indirectly compare the efficacy of novel systemic therapies for urothelial cancer using phase 3 trial data.

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...

The primary endpoints of TROPION-Lung02 are dose-limiting toxicities and treatment-emergent adverse events. Secondary endpoints include ORR, DoR, PFS as assessed by investigator, overall survival, ...

A grandad diagnosed with stage 4 lung cancer–one of the deadliest—has become disease-free after being treated with an ...